Aptevo Therapeutics Inc. (APVO) Key Statistics & Financial Ratios

Aptevo Therapeutics Inc. (APVO) — Price $1.72 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Aptevo Therapeutics Inc. (APVO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes.

Stock Data

Price$1.72
Market Cap$4M
Enterprise Value-$1.8M
Beta1.51
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-0.01
Price / Book0.34
P/S0.00
EV/EBITDA0.07
EV/Sales0.00
EV/FCF0.07
P/FCF-0.15
Earnings Yield-1283.35%
FCF Yield-673.77%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity-201.49%
Return on Assets-181.89%
Return on Invested Capital-262.30%
Return on Capital Employed-288.14%

Financial Health

Current Ratio2.08
Quick Ratio2.08
Cash Ratio1.89
Debt / Equity0.70
Debt / Assets28.99%
Net Debt / EBITDA0.21
Interest Coverage0.00

Per-Share Data

Revenue per share0.00
Book Value per share5.05
Cash per share8.19
FCF per share-21.18
Tangible Book Value per share5.05
Dividend per share0.00

Related companies: ABP · BCDA · CERO · EPIX · ERNA · HCWB · INAB

Explore sector: Healthcare · Biotechnology

More sections of APVO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks